ACLARIS THERAPEUTICS DL 1 WKN: A1412H ISIN: US00461U1051 Kürzel: ACRS Forum: Aktien Thema: Hauptdiskussion

Hier die Erklärung für den Absturz statt den Anstieg. Das Konkurrenzprodukt von Pfizer schnitt im Ranking besser ab: Aclaris’s alopecia Jak might not be worth its Salt https://www.evaluate.com/vantage/articles/news/snippets/aclariss-alopecia-jak-might-not-be-worth-its-salt Zusätzlich strengen einige Anwaltskanzleien Ermittlungen gegen Aclaris an: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aclaris Therapeutics, Inc. (ACRS) On June 20, 2019, the U.S. Food & Drug Administration (“FDA”) asserted that an Aclaris advertisement for its Eskata hydrogen peroxide topical solution “makes false or misleading claims” regarding the product’s risk and efficacy. Specifically, the FDA stated that “a direct-to-consumer video of an interview featuring a paid Aclaris spokesperson” was “especially concerning from a public health perspective because it fails to include information regarding the serious risks associated with Eskata, which bears warnings and precautions related to the risks of serious eye disorders . . . in the case of exposure to the eye and severe skin reactions including scarring.”  https://finance.yahoo.com/news/bronstein-gewirtz-grossman-llc-announces-141500784.html

No risk, No fun. Wie viele Shares habt ihr so und zu welchem Kurs?

Hab mir mal 2000 Stück gegönnt👌🏾

Ja eig schon... Kurs sagt was anderes.

Hört sich gut an...👌🏻

Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint    July 30, 2019 16:01 ET | Source: Aclaris Therapeutics, Inc. ATI-501 achieved statistically significant improvement over placebo in several measures of hair growth, including the primary endpoint and certain secondary endpoints of the trial. ATI-501 was generally well-tolerated at all doses.  No serious adverse events or thromboembolic events were reported during the trial. Patient population included moderate to severe Patchy Alopecia, Alopecia Universalis, and Totalis https://www.globenewswire.com/news-release/2019/07/30/1894010/0/en/Aclaris-Therapeutics-Announces-Phase-2-Clinical-Trial-of-ATI-501-Oral-in-Patients-with-Alopecia-Areata-Met-Primary-Endpoint.html

Danke fürs einstellen

Ich finde Aclaris hat im Moment den idealen Einstiegspreis. Der Boden scheint gefunden und jetzt kann es wieder aufwärts gehen. RSI zeigt überverkauft an, SMI und MACD sind wieder auf "buy". Das Preisziel wurde von 50$ auf 24$ reduziert (https://www.google.com/amp/s/mayfieldrecorder.com/2019/07/07/cantor-fitzgerald-trims-aclaris-therapeutics-nasdaqacrs-target-price-to-24-00.html/amp). Die Aktie ist abgestürzt weil die Phase 2 Clinical Trial von ATI-502 Topical das Ziel verfehlte. https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-phase-2-clinical-trial-ati-502 Sie bekamen aber kürzlich ein Patent zugesprochen: Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-issuance-additional-orange-book-0 In Q3 stehen noch Studienergebnisse zu: - A-101 45% Topical Solution (THWART-1, THWART-2 und safety) - AGA-201 Topical - VITI-201 Topical - AD-201 Topical - AUAT-201 Oral  https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-first-quarter-2019-financial Cash ist im Moment bis Ende 2020 vorhanden und beträgt 137 Mio$, bei aktuell vorhandener Marktkapitalisierung von 86,6Mio$ also etwas mehr als das 1,5-fache.

Ok wenn ich es richtig verstehe ist es super das sie keine Umsatzgeschäfte bis Ende 2020 benötigen um den Betrieb am laufen zu halten. Sie aber im 1.Quartal nen Nettoumsatz von 3,7Mio hatten

Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments May 8, 2019 Submitted IND for ATI-450, an oral MK2 inhibitor RHOFADE net sales of $3.7 million for the first quarter of 2019 Management to Host Conference Call at 5:00 PM ET today Financial Highlights: Liquidity and Capital Resources As of March 31, 2019, Aclaris had aggregate cash, cash equivalents and marketable securities of $136.8 million compared to $168.0 million as of December 31, 2018. The $31.2 million decrease during the quarter ended March 31, 2019 included: Net loss of $37.6 million, $0.8 million of net cash used in working capital, and $0.3 millionin property and equipment purchases. These uses were offset by $4.9 million of non-cash stock-based compensation expense and $2.2 million of non-cash depreciation and amortization expense. Aclaris anticipates that its cash, cash equivalents and marketable securities as of March 31, 2019 will be sufficient to fund its operations into the fourth quarter of 2020, without giving effect to any potential new business development transactions or financing activities. http://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-first-quarter-2019-financial

👋👋👋